Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$45.89
$42.32
$10.71
$46.95
$2.44B1.091.50 million shs2.41 million shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.23
+0.4%
$15.76
$13.09
$18.92
$6.15B0.56352,448 shs492,548 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$147.49
-0.6%
$129.31
$73.16
$148.62
$8.66B0.75882,314 shs1.24 million shs
Liquidia Corporation stock logo
LQDA
Liquidia
$78.93
$60.77
$11.86
$80.69
$7.02B0.552.49 million shs1.41 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
0.00%+2.14%+7.22%+40.59%+320.24%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+5.76%+11.31%+5.34%+24.60%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+2.16%+18.19%+26.64%+42.50%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+0.97%+27.62%+109.64%+544.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$45.89
$42.32
$10.71
$46.95
$2.44B1.091.50 million shs2.41 million shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.23
+0.4%
$15.76
$13.09
$18.92
$6.15B0.56352,448 shs492,548 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$147.49
-0.6%
$129.31
$73.16
$148.62
$8.66B0.75882,314 shs1.24 million shs
Liquidia Corporation stock logo
LQDA
Liquidia
$78.93
$60.77
$11.86
$80.69
$7.02B0.552.49 million shs1.41 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
0.00%+2.14%+7.22%+40.59%+320.24%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+5.76%+11.31%+5.34%+24.60%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+2.16%+18.19%+26.64%+42.50%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+0.97%+27.62%+109.64%+544.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
2.73
Moderate Buy$46.501.33% Upside
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$17.923.97% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$149.171.14% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.82
Moderate Buy$68.88-12.74% Downside

Current Analyst Ratings Breakdown

Latest AXGN, GKOS, BLCO, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingOverweight$165.00
6/29/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingBuyNeutral$64.00 ➝ $79.00
6/22/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$59.00 ➝ $109.00
6/17/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$136.00 ➝ $150.00
6/11/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$140.00 ➝ $162.00
6/10/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingBuy$162.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$67.00 ➝ $75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$28.00
6/4/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingStrong-Buy$68.00
6/2/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price TargetBuy$19.00
(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$225.21M10.84N/AN/A$2.79 per share16.45
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.21$1.68 per share10.28$18.40 per share0.94
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M17.07N/AN/A$11.42 per share12.92
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M44.34N/AN/A$0.51 per share154.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$15.70M-$0.64N/A169.96N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A16.100.53-4.21%3.60%1.69%7/29/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A313.81N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$0.14563.7916.04N/A7.74%46.82%7.06%8/11/2026 (Estimated)

Latest AXGN, GKOS, BLCO, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2026Q2 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16N/AN/AN/A$1.37 billionN/A
7/29/2026Q2 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.2136N/AN/AN/A$151.13 millionN/A
5/11/2026Q1 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
4/28/2026Q1 2026
AxoGen, Inc. stock logo
AXGN
AxoGen
$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.08
7.10
5.33
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
Liquidia Corporation stock logo
LQDA
Liquidia
1.18
2.22
2.03

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.44%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
45053.18 million51.88 millionOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.04 million351.87 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.27 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5088.93 million66.16 millionOptionable

Recent News About These Companies

Is Liquidia Corporation (LQDA) A Good Stock To Buy Now?
Wall Street Zen Downgrades Liquidia (NASDAQ:LQDA) to Buy

New MarketBeat Followers Over Time

Media Sentiment Over Time

AxoGen stock logo

AxoGen NASDAQ:AXGN

$45.89 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$46.52 +0.63 (+1.38%)
As of 07/2/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$17.23 +0.07 (+0.42%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$17.14 -0.09 (-0.50%)
As of 07/2/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$147.49 -0.85 (-0.57%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$148.33 +0.84 (+0.57%)
As of 07/2/2026 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$78.93 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$78.84 -0.09 (-0.12%)
As of 07/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.